drug · small molecule
PAXLOVID (COPACKAGED)
Marketedupdated 3mo agoby $PFE PFIZER INC🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3Small molecule drug with a maximum clinical stage of Approval (across all indications), with 4 investigational indications.
targets
Replicase polyprotein 1a
all catalysts(7)
approval · 7
May 25, 2023
approval
$PFE26.87+0.30%
PAXLOVID (COPACKAGED) (NIRMATRELVIR) — FDA approval
PAXLOVID (COPACKAGED)
→
Sep 12, 2024
approval
$PFE26.87+0.30%
PAXLOVID (COPACKAGED) (NIRMATRELVIR) — FDA approval
PAXLOVID (COPACKAGED)
→
Nov 19, 2024
approval
$PFE26.87+0.30%
PAXLOVID (COPACKAGED) (NIRMATRELVIR) — FDA approval
PAXLOVID (COPACKAGED)
→
Jan 31, 2025
approval
$PFE26.87+0.30%
PAXLOVID (COPACKAGED) (NIRMATRELVIR) — FDA approval
PAXLOVID (COPACKAGED)
→
Feb 12, 2025
approval
$PFE26.87+0.30%
PAXLOVID (COPACKAGED) (NIRMATRELVIR) — FDA approval
PAXLOVID (COPACKAGED)
→
Feb 11, 2026
approval
$PFE26.87+0.30%
PAXLOVID (COPACKAGED) (NIRMATRELVIR) — FDA approval
PAXLOVID (COPACKAGED)
→
Feb 11, 2026
approval
$PFE26.87+0.30%
PAXLOVID (COPACKAGED) (NIRMATRELVIR) — FDA approval
PAXLOVID (COPACKAGED)
→
Trials studying PAXLOVID (COPACKAGED)
- phase1A Study to Learn About the Study Medicine (Nirmatrelvir Plus Ritonavir) in Pregnant Women With COVID-19
- —A Study to Learn About the Study Medicine Paxlovid (Nirmatrelvir + Ritonavir) in Adults Aged 60 and Older Living in Korean Long-term Care Hospitals Who Have COVID-19
- —A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming Severe
- phase1A Study on 2 Different Combination Tablets of Nirmatrelvir Plus Ritonavir to Compare Them With Marketed Paxlovid in Healthy Participants
- —A Study to Learn How Paxlovid [Nirmatrelvir-ritonavir/PF-07321332] Works in COVID-19 Patients Who Are Elderly or Have Medical Conditions.
- phase2Paxlovid for Treatment of Long Covid
- —A Study to Learn About PAXLOVID (a Commercial Medicine) In People With COVID-19
- —A Study to Learn About the Use of Paxlovid in Patients With COVID-19 in the Kingdom of Bahrain.
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jan 31, 2028
~1.5 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (2)
- Oct 31, 2041method-of-use (U-3629)US 11541034
- Aug 5, 2041compositionUS 11351149
FDA exclusivities (2)
- May 25, 2028NCENew Chemical Entity (5y)1.8y
- Jan 31, 2028D-195New Indication (3y)1.5y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 12m ago
Found something off?
comments(0)
5-min edit window · permanent after that